Do GLP-1 receptor agonists, SGLT-2 inhibitors, or DPP-4 inhibitors reduce the risk of severe COPD exacerbations compared with sulfonylureas in patients with COPD and type 2 diabetes?
GLP-1 receptor agonists and SGLT-2 inhibitors may reduce the risk of severe COPD exacerbations in patients with concurrent type 2 diabetes compared to sulfonylureas.
In this population based study, GLP-1 receptor agonists and SGLT-2 inhibitors were associated with a reduced risk of severe exacerbations compared with sulfonylureas in patients with chronic obstructive pulmonary disease and type 2 diabetes. DPP-4 inhibitors were not clearly associated with a decreased risk of chronic obstructive pulmonary disease exacerbations.
Pradhan et al. (Tue,) studied this question.